// App-Quantinova.ai

: Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin in bronchiectasis: results from the ORBIT-3 and -4 studies

Researchers

Presenter

  • James D. Chalmers

Principal Investigators

  • David Cipolla

  • Bruce Thompson

  • Angela M Davis

  • Anne O'Donnell

  • Gregory Tino

  • Igor Gonda

  • Charles Haworth

  • Juergen Froehlich

Medical Centers

  • University of Dundee, Dundee, United Kingdom

  • Aradigm Corporation, Hayward, United States of America

  • Theta Hat Statistical Consultants, Owings Mills, United States of America

  • Grifols, Clayton, United States of America

  • University of Pennsylvania, Philadelphia, United States of America

  • Aradigm Corporation, Hayward, United States of America

  • Papworth Hospital, Cambridge, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Liposomal ciprofloxacin

  • ARD-3150

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved